Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Brigham and Women's Hospital
M.D. Anderson Cancer Center
Stanford University
M.D. Anderson Cancer Center
Eli Lilly and Company
Taichung Veterans General Hospital
Bayer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services
National Taiwan University Hospital
National Taiwan University Hospital